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Abstract
Summary A fracture risk assessment tool (FRAX™)i s
developed based on the use of clinical risk factors with or
without bone mineral density tests applied to the UK.
Introduction The aim of this study was to apply an
assessment tool for the prediction of fracture in men and
women with the use of clinical risk factors (CRFs) for
fracture with and without the use of femoral neck bone
mineral density (BMD). The clinical risk factors, identified
from previous meta-analyses, comprised body mass index
(BMI, as a continuous variable), a prior history of fracture,
a parental history of hip fracture, use of oral glucocorti-
coids, rheumatoid arthritis and other secondary causes of
osteoporosis, current smoking, and alcohol intake 3 or more
units daily.
Methods Four models were constructed to compute fracture
probabilities based on the epidemiology of fracture in the
UK. The models comprised the ten-year probability of hip
fracture, with and without femoral neck BMD, and the ten-
year probability of a major osteoporotic fracture, with and
without BMD. For each model fracture and death hazards
were computed as continuous functions.
Results Each clinical risk factor contributed to fracture
probability. In the absence of BMD, hip fracture probability
in women with a fixed BMI (25 kg/m
2) ranged from 0.2%
at the age of 50 years for women without CRF’s to 22% at
the age of 80 years with a parental history of hip fracture
(approximately 100-fold range). In men, the probabilities
were lower, as was the range (0.1 to 11% in the examples
above). For a major osteoporotic fracture the probabilities
ranged from 3.5% to 31% in women, and from 2.8% to
15% in men in the example above. The presence of one or
more risk factors increased probabilities in an incremental
manner. The differences in probabilities between men and
women were comparable at any given T-score and age,
except in the elderly where probabilities were higher in
women than in men due to the higher mortality of the latter.
Conclusion The models provide a framework which
enhances the assessment of fracture risk in both men and
women by the integration of clinical risk factors alone and/
or in combination with BMD.
Keywords Clinicalriskfactors.Fractureprobability.
FRAX™.Osteoporoticfracture
Introduction
Several multi-factorial diseases (e.g., diabetes, hypertension)
are defined on the basis of important risk factors for the
clinical outcome. Hypertension, for example, is defined from
the measurement of blood pressure that provides information
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Sheffield, UKon the likelihood of stroke. Hypercholesterolaemia and
osteoporosis are also examples. In the case of osteoporosis,
bone mineral density (BMD) is measured both to provide a
diagnosis, and to yield information on fracture risk [1].
Many well-controlled prospective studies with dual
energy X-ray absorptiometry (DXA), particularly in elderly
women, indicate that the risk of fracture about doubles for
each SD reduction in BMD [2, 3]. The measurement of a
risk factor for diagnostic use, however, can only capture
one aspect of the likelihood of the outcome when the
disease is multifactorial, and in osteoporosis, assessment
with BMD captures a minority of the fracture risk. For
example, the annual incidence of hip fracture increases
approximately 30-fold between the ages of 50 and 90 years;
but, from the known relationship between BMD and
fracture risk and the loss of bone with age, it is expected
that hip fracture risk would rise only fourfold [4–6]. Thus,
the increase in risk with age is approximately sevenfold
greater than can be explained on the basis of BMD alone.
The imperfect capture of risk with BMD alone poses
several problems for the clinical assessment of fracture risk.
In the context of population screening with BMD alone, the
performance characteristics of the test are less than optimal
in terms of the trade-off between sensitivity and specificity
[1, 7, 8]. Thus, osteoporotic fractures affect a substantial
minority of the population, but intervention thresholds based
on BMD alone lack sensitivity over most reasonable
assumption, i.e., the detection rate is low. For example, at
the age of 50 years the proportion of women with
osteoporosis is approximately 5% [4]. The proportion of
these who will fracture in the next 10 years (i.e., positive
predictive value) is about 20%. The detection rate for these
fractures (sensitivity) is, however, low, and 96% of fragility
fractures would arise in women without osteoporosis given a
test like BMD where the fracture risk doubled for each SD
decrease [9]. Low sensitivity is one of the reasons why wide-
spread population screening is not widely recommended in
women at the menopause [1]. Moreover, a normal BMD
measurement is no guarantee that a fracture will not occur.
The use of risk factors that add information on fracture
risk independently of BMD improves the sensitivity of the
assessment for any specificity [8, 9]. Over the past several
years, we have undertaken a series of meta-analyses to
identify clinical risk factors for fracture that provide
independent information on fracture risk [3, 10–16]. The
analyses were based on the primary data from prospective
population based studies. This permits the inter-dependence
of each of the candidate risk factors to be examined so that
they can be accurately combined for clinical use. In the case
of the clinical risk factors, BMI is used as a continuous
variable, so that its distribution is preserved by the addition
of dichotomous variables [8]. For hip fracture prediction,
the gradient of risk (increase in fracture risk per standard
deviation increase in risk score) for the CRFs is comparable
to the use of DXA alone, and the gradient of risk is further
enhanced by the addition of BMD to the CRFs [17]. These
inter-relationships, assessed from multiple populations and
validated in independent cohorts, permit the more accurate
identification of individuals who will fracture, so that the
average risk in any given proportion of the population
identified for treatment will be higher [8].
These considerations indicate that assessment can be
improved by the integration of clinical risk factors with or
without BMD. In other words, treatment should be directed
not only on the basis of T-score for BMD, but also on the
independent contribution of other validated risk factors.
However, the use of different metrics (the T-score, gradients
of risk, risk ratios, etc) is confusing for clinicians and
patients alike. For this reason, there has been interest in the
development of algorithms that express absolute risk, or the
probability of fracture within a given time period [18–20],
as has been done for cardiovascular and other diseases [21–
25]. The aim of the present study was to develop a model
for the clinical assessment of fracture probability in men
and women based on the epidemiology of the UK.
Methods
Cohorts
In order to identify the relevant risk factors, we used
baseline and follow-up data from nine prospective popula-
tion-based cohorts comprising the Rotterdam Study, The
European Vertebral Osteoporosis Study (later the European
Prospective Osteoporosis Study (EVOS/EPOS), The Cana-
dian Multicentre Osteoporosis Study (CaMos), Rochester,
Sheffield, Dubbo, a cohort from Hiroshima and two cohorts
from Gothenburg. Details of each of the cohorts have been
recently published elsewhere [10–16].
Baseline and outcome variables
Height and weight were measured using standard tech-
niques in all cohorts. Body mass index (BMI) was calculated
as weight divided by height squared (kg/m
2) and used as a
continuous variable. BMD was assessed at the femoral neck
by DXA with the exception of the two Gothenburg cohorts
in which BMD was measured elsewhere. Femoral neck
BMD was used as a continuous variable (cohort-specific
Z-scores excluding the two cohorts from Gothenburg). The
clinical risk factors utilised were those identified from the
previous meta-analyses [3, 10–16]. These comprised a
parental history of hip fracture, exposure to systemic
glucocorticoids, a prior history of fragility fracture, current
smoking, high intake of alcohol (3 or more units daily on
386 Osteoporos Int (2008) 19:385–397average) and the presence of rheumatoid arthritis as an
indicator for secondary osteoporosis.
Fracture ascertainment in the primary cohorts was
undertaken by self-report (Sheffield, EVOS/EPOS, Hiro-
shima) and/or verified from hospital or central data-bases
(Gothenburg, CaMos, DOES, Sheffield, EVOS/EPOS,
Rochester, Rotterdam).
Models used
Four models were constructed from the risk factor analysis to
compute fracture probabilities. These comprised the probabil-
ity of hip fracture, with and without BMD, and the probability
of other major osteoporotic fractures (clinical spine, forearm
and proximal humerus), with and without BMD. For each
model,fractureanddeathascontinuoushazardfunctionswere
computed using a Poisson regression [26, 27] and detailed in
the Appendix. In brief, for each risk factor, all significant
interactions terms that were identified by meta-analysis were
entered (with age, time, sex and the risk factor) with and
without BMD [17]. Interactions that were significant for hip
fracture risk were also entered into the model for other
osteoporotic fractures, and also included in the model for
death. Where interactions noted in the “mega-analyses” were
no longer significant for both hip fracture and other
osteoporotic fractures, these were omitted in a step-wise
manner by dropping the interaction with the largest p value.
For the death hazard, all significant interactions for fracture
risk were included and thereafter omitted if appropriate in a
step-wise manner, as described for the fracture hazard.
Epidemiology
Theincidenceofhip,forearmandproximalhumerusfractures
in the UK was taken from Singer et al. [28]. Vertebral
fractures can be classified as clinically overt fracture, that is,
a symptomatic fracture that comes to clinical attention, or a
morphometric fracture, which includes both symptomatic
and asymptomatic fractures. For the purposes of this study
the clinical definition of a vertebral fracture was used.
Because data on vertebral fracture risk in the UK are scarce,
with a great deal of variation in reported rates [29], the
clinical vertebral fracture incidence was calculated by
assuming that the ratio of clinical vertebral fracture to hip
fracture would be similar in the UK compared to Sweden
[30]. The validity of the assumption cannot be directly
tested, but in the case of long bone fractures, there is a close
concordance of relative incidence at different fracture sites
despite marked differences in absolute risk [31]. Swedish
fracture risk data were taken from Kanis et al. [32]. The
models were then calibrated so that the mean hazard
functions of fracture (and death) equalled that of the UK,
as detailed in the Appendix.
Input and output variables
Individual patient details comprise age (50 to 90 years),
sex, weight (in kg) and height (in cm). BMI is automati-
cally computed from height and weight. Dichotomised risk
variables are then entered:
– A prior fragility fracture (yes/no)
– Parental history of hip fracture (yes/no)
– Current tobacco smoking (yes/no)
– Ever long-term use of oral glucocorticoids (yes/no)
– Rheumatoid arthritis (yes/no)
– Other causes of secondary osteoporosis (yes/no)
– Daily alcohol consumption of three or more units daily
(yes/no)
A distinction is made between rheumatoid arthritis and
other secondary causes of osteoporosis. Rheumatoid arthri-
tis carries a fracture risk over and above that provided by
BMD [11]. Whereas this may hold true for other secondary
causes of osteoporosis, the evidence base is weak. Of the
many secondary causes of osteoporosis, the following have
been consistently documented to be associated with a
significant increase in fracture risk:
– Untreated hypogonadism in men and women, e.g.,
bilateral oophorectomy or orchidectomy, anorexia
nervosa, chemotherapy for breast cancer, hypopituita-
rism [33–40]
– Inflammatory bowel disease, e.g., Crohn’s disease and
ulcerative colitis [41–43]. It should be noted that the
risk is in part dependent on the use of glucocorticoids,
but an independent risk remains after adjustment for
glucocorticoid exposure [44].
– Prolonged immobility, e.g., spinal cord injury, Parkin-
son’s disease, stroke, muscular dystrophy, ankylosing
spondylitis [45–50]
– Organ transplantation [51–54]
– Type I diabetes [55–58]
– Thyroid disorders, e.g., untreated hyperthyroidism,
over-treated hypothyroidism [59–63]
Whereas there is strong evidence for the association of
these disorders and fracture risk, the independence of these
risk factors from BMD is uncertain. It was conservatively
assumed, therefore, that the fracture risk was mediated via
low BMD, but with a risk ratio similar to that noted in
rheumatoid arthritis. From an operational view, where the
field for rheumatoid arthritis is entered as ‘yes’, a risk is
computed with and without BMD. If the field for other
secondary osteoporosis is also filled as ‘yes’ this does not
contribute to the calculation of fracture probability. Con-
versely, where the field for rheumatoid arthritis entered as
‘no’, and the field for secondary osteoporosis is ‘yes’, the
same β coefficients as used for rheumatoid arthritis
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not entered. In the presence of BMD, however, no
additional risk is assumed in the presence of secondary
osteoporosis, since its independence of BMD is uncertain.
If any of the fields for dichotomous variables is not
completed, a negative response is assumed. Fractures
probability can then be calculated. The output (without
BMD) comprises the 10-year probability of hip, clinical
spine, shoulder or wrist fracture and the 10-year probability
of hip fracture (Fig. 1).
Femoral neck BMD can additionally be entered either as
a Z-score or a T-score. The transformation of Z- to T-score
and vice versa is derived for the NHANES III database for
female Caucasians aged 20–29 years [64]. When entered,
calculations give the 10-year probabilities as defined above
with or without the inclusion of BMD.
Results
Clinical risk factors
The contribution of single clinical risk factors is shown
in Table 1 for men and women aged 65 years. In the
example, the BMI is set at 25 kg/m
2. In the absence of
BMD, hip fracture probabilities were higher in women
than in men. Each clinical risk factor had a different
significance for hip fracture probability, with a family
history having the least and a prior fracture the greatest
weight in the absence of BMD. The rank order of
weighting differed for the major osteoporotic fractures.
For example, a parental history of hip fracture was a
strong risk factor, close to that provided by a prior fragility
fracture. The contribution of age to the assessment of
probability is shown in Table 2.I nb o t hm e na n dw o m e n ,
there was greater than 100-fold difference in hip fracture
probability between the age of 50 years (no risk factors)
and 80 years (parental history of hip fracture).
The presence of more than one risk factor increased
fracture probability in an incremental manner. For example,
in women aged 65 years with a BMI of 25 kg/m
2, the 10-year
hip fracture probability was 1.3%. With one clinical risk
factor, the probability ranged from 1.7% to 3.2%, depending
on the risk factor. With two risk factors, the range was 2.5–
6.6%, and with 3, 4 and 5 risk factors the ranges were 3.8–
11%, 6.7–17% and 13–24%, respectively. In the presence of
all six clinical risk factors, the 10-year probability of hip
fracture was 30%.
The effect of several clinical risk factors on the 10-year
probability of a major osteoporotic fracture is shown in
Fig. 2 for a woman aged 65 years and a BMI of 25 kg/m
2.
In women with rheumatoid arthritis, there was a 33%
increase in fracture probability compared with those
without rheumatoid (from 9% to 12%). When women
additionally took oral glucocorticoids and had a prior
fracture there was a fourfold increase in fracture probability.
Fig. 1 Input and output for the FRAX™ model
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probability (Fig. 3). For example, in women at the age of
65 years the 10-year hip fracture probability in the absence
of risk factors was 2.3% with a BMI of 20 kg/m
2, but was
fourfold lower (0.6%) at a BMI of 40 kg/m
2. At each level
of BMI, fracture probability increased with an increasing
number of clinical risk factors.
Bone mineral density
The relationship between fracture probability and BMD is
shown in Table 3. In general, fracture risk increased with
increasing age and decreasing T-score. At low T-scores,
however, fracture probabilities decreased with age, a
phenomenon more marked in men than in women. For
example, at the age of 50 years, the 10-year probability of
hip fracture was 16.0% in men with a T-score of −4 SD and
this fell progressively with age, so that at the age of
70 years, the probability was 12.9% and at the age of
90 years was 8.3%.
The differences in probabilities between men and
women were much less marked for any given age and
T-score than the differences seen with the use of clinical
risk factors alone. At a fixed BMD (−2.5 SD in Table 1),
the difference in probability between men and women was
less evident. For example, the hip fracture probability ratio
Table 2 Ten-year probability of fracture (%) at the sites shown for men and women with a BMI of 25 kg/m
2 according to age and the presence or
absence of a single risk factor in the absence of BMD
Osteoporotic fracture
a Hip fracture
50 60 70 80 50 60 70 80
(a) Men
No clinical risk factors 2.8 3.9 5.7 7.2 0.1 0.4 1.3 3.4
Parental history of hip fracture 5.5 7.6 9.1 15 0.2 0.6 2.8 11
Current cigarette smoking 2.8 4.1 5.9 7.5 0.2 0.7 1.8 4.2
Alcohol intake >2 units daily 3.3 4.7 7.1 9.5 0.2 0.7 2.0 5.1
Rheumatoid arthritis 3.7 5.3 8.0 11 0.2 0.8 2.3 5.8
Oral glucocorticoids 4.4 6.1 8.5 10 0.3 0.9 2.4 5.5
Previous fragility fracture 5.8 7.9 11 12 0.5 1.3 2.7 5.2
(b) Women
No clinical risk factors 3.5 6.0 11 17 0.2 0.7 2.3 7.0
Parental history of hip fracture 6.9 12 17 31 0.3 0.9 5.0 22
Current cigarette smoking 3.6 6.5 12 19 0.3 1.1 3.4 9.5
Alcohol intake >2 units daily 4.1 7.3 14 22 0.3 1.1 3.6 10
Rheumatoid arthritis 4.7 8.2 15 25 0.4 1.3 4.1 12
Oral glucocorticoids 5.6 9.8 18 26 0.5 1.5 4.8 13
Previous fragility fracture 7.4 12 20 28 0.8 2.1 4.9 11
aClinical spine, hip, humeral or forearm fracture
Table 1 Ten-year probability (%) of a major osteoporotic fracture or hip fracture in men and women aged 65 years according to the presence of a
single clinical risk factor
Without BMD T-score −2.5 SD
Men Women Men Women
Osteoporotic
a Hip Osteoporotic
a Hip Osteoporotic
a Hip Osteoporotic
a Hip
No clinical risk factors 4.9 0.8 8.6 1.3 9.8 3.6 12.4 3.0
Parental history of hip fracture 9.3 1.0 16.0 1.7 16.5 3.7 22.1 3.2
Current cigarette smoking 5.1 1.1 9.2 1.9 11.0 5.6 13.7 5.1
Alcohol intake >2 units daily 6.0 1.2 10.4 2.0 12.5 5.4 15.4 4.6
Rheumatoid arthritis 6.8 1.4 11.7 2.3 12.8 5.0 16.1 4.3
Oral glucocorticoids 7.5 1.5 13.7 2.7 15.0 6.1 19.7 5.5
Previous fragility fracture 9.6 1.9 16.4 3.2 16.0 5.9 20.2 5.0
BMI is set at 25 kg/m
2. The right-hand panels show probabilities at a T-score of −2.5 SD at the femoral neck
aHip, clinical spine, humeral or forearm fracture
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absence of BMD but 0.9 at a T-score of −2.5 SD. In the
case of all major osteoporotic fractures, probabilities
remained higher in women than in men at a T-score of
−2.5 SD but the difference in probabilities between men
and women was less marked.
Figure 4 compares the probability of hip fracture in men
and women with a prior fracture according to age. In the
absence of BMD there was approximately a twofold
difference in probability between men and women. When
the BMD was set at an average for women (Z-score=0),
there was little difference in probabilities up to the age of
75 years. Thereafter, men had a lower probability than
women due to the higher death hazard.
The clinical risk factors added to the information
provided by BMD. Isopleths for 10-year fracture probabil-
ity are shown in Fig. 5 for the combination of several of the
clinical risk factors. The clinical risk factors were somewhat
less predictive in the presence of BMD in the models. For
example, in women aged 65 years and a BMI of 20 kg/m
2,
the 10-year hip fracture probability in the absence of BMD
ranged from 2.3% in the absence of clinical risk factors to
27.9% with four risk factors. When BMD was set constant
at a T-score of −2.5 SD, the range was from 2.8% with no
clinical risk factor to 19.7% with four risk factors (Fig. 6).
The effect of variations in BMI was even more markedly
affected by BMD. For example, in women aged 65 years
the 10-year hip fracture probability was 2.3% at a BMI of
20 kg/m
2 and decreased progressively at higher levels of
BMI to 0.6% with a BMI of 40 kg/m
2. When BMD was
fixed, hip fracture probability remained constant irrespec-
tive of BMI (Fig. 7).
Discussion
The present study provides a model for the assessment of
fracture probability in men and women. The model
(FRAX™) uses data derived from nine cohorts from around
the world, including centres from North America, Europe,
Asia and Australia and has been validated in 11 indepen-
dent cohorts with a similar geographic distribution [17].
The use of primary (but anonymized) data for the model
construct permits the interaction of each of the risk factors
to be determined to improve the accuracy whereby fracture
probability can be computed. The large sample permitted
the examination of the general relationship of each risk
factor by age, sex, duration of follow up and, for
continuous variables (BMD and BMI), the relationship of
risk with the variable itself in a manner hitherto not
possible. The use of primary data also eliminates the risk
of publication bias. The validity of the clinical risk factors
0.1
1.0
10.0
100.0
0123456 0123456
Number of clinical risk factors
Ten-year probability (%)
BMI = 20                                  BMI = 40
Fig. 3 Ten-year probability of hip fracture (%) in women aged
65 years according to the number of clinical risk factors with a BMI of
20 kg/m
2 (left-hand panels) and a BMI of 40 kg/m
2 (right-hand
panels). The intervals reflect the different weights afforded by
different risk factors and provide a range of probabilities. [05Ca070]
No
No No
Woman aged 65, BMI=25
Yes
Yes Yes
Yes No Yes No Yes No Yes No
16 35 14 19 22 12 26 8
Rheumatoid arthritis
Glucocorticoids
Prior fracture
10-year fracture
probability (%)
Fig. 2 Effect of combinations
of clinical risk factors on the
10-year probability of a major
osteoporotic fracture in women
aged 65 years and a BMI of
25 kg/m
2. [05Ca201]
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between BMD and fracture risk [3].
In the present study, the FRAX™ model has been
calibrated to the epidemiology of the UK, but could be
calibrated to any country where the epidemiology of
fracture and death is known (see Appendix). FRAX™
models for the UK and some other countries are available
through the web (http://www.shef.ac.uk/FRAX/index.htm).
The approach uses easily obtained clinical risk factors to
estimate risk. The estimate can be used alone or with BMD
to enhance fracture risk prediction.
Several previous studies have developed models to
predict fracture risk from the combination of clinical risk
factors and BMD [18, 65–78]. The risk factors used include
Table 3 Ten-year fracture probability (%) in men and women from the UK with a BMI of 25 kg/m
2 and no clinical risk factors according to age
and T-score at the femoral neck
Age T-score (SD)
(years) +1 0 −1 −2 −3 −4
(a) Hip fracture men
50 <0.1 0.1 0.4 1.3 4.7 16.0
60 0.1 0.2 0.6 1.9 5.6 15.6
70 0.2 0.5 1.1 2.6 5.9 12.9
80 0.6 1.1 1.9 3.4 6.1 10.7
90 1.2 1.8 2.5 3.8 5.6 8.3
(b) Hip fracture women
50 <0.1 0.1 0.2 0.8 3.2 11.7
60 0.1 0.2 0.4 1.4 4.4 13.5
70 0.1 0.4 0.9 2.4 6.3 16.2
80 0.5 1.0 2.1 4.4 9.5 19.7
90 1.2 2.0 3.5 5.8 9.8 16.9
(c) Osteoporotic fracture
a - men
50 2.5 2.7 3.5 5.1 9.2 20.9
60 3.0 3.5 4.5 6.8 11.5 22.2
70 3.6 4.3 5.5 8.2 12.8 20.9
80 3.2 4.0 5.2 7.6 11.3 16.9
90 3.1 3.9 5.1 6.9 9.7 13.5
(d) Osteoporotic fracture
a - women
50 3.0 3.3 3.8 5.2 8.5 17.7
60 4.2 4.8 5.6 7.9 12.6 23.0
70 5.6 6.8 8.4 11.5 18.2 30.4
80 5.8 7.5 10.1 13.8 21.7 34.3
90 5.1 7.1 9.9 13.8 20.0 30.3
aHip, clinical spine, humerus or forearm fracture
0
5
10
15
20
50 55 60 65 70 75 80 85
Men
Women
0
5
10
15
20
50 55 60 65 70 75 80 85
Without BMD                                     Average BMD for women
(Z-score=0)
Probability (%)
Age (years)
Fig. 4 Ten-year hip fracture
probability (%) in men and
women with a prior fracture
according to age. The left-hand
panel gives probabilities in the
absence of BMD. In the right-
hand panel probabilities are
shown at an average BMD for
women at each specific age (i.e.,
a Z-score = 0). A BMI is set at
24 kg/m
2. [05Ca065]
Osteoporos Int (2008) 19:385–397 391activities of daily living, impaired cognition, liability to
falls, poor overall health, history of stroke, seizure disorder
and several different medications. A limitation of many of
these studies is that, with the exception of the SOF study
[18], and one of the GPRD studies [76], they have not been
tested in other cohorts. The model described in this paper
has been validated in 11 independent prospectively studied
cohorts with in excess of one million patient years [17].
The use of risk factors for case finding presupposes that
the risk so identified is responsive to a therapeutic
intervention. To test this hypothesis, it would be necessary
to recruit patients selected on the basis of the risk factor(s)
to a randomised controlled trial (RCT). The risk factor that
is best evaluated in this way is BMD, and indeed the vast
majority of therapeutic studies have recruited patients on
the basis of low BMD as recommended by regulatory
agencies in the US and Europe [79, 80]. In recent years,
other trials have recruited patients on the basis of age,
gender, a prior vertebral fracture and current exposure to
glucocorticoids irrespective of BMD, and have shown
therapeutic effects similar to those noted in RCT’s based
on BMD selection [14, 81–83].
For other risk factors, comparable data are lacking. In the
absence of empirical data, an alternative approach is to
demonstrate that the presence (or absence) of a risk factor
does not adversely influence therapeutic efficacy against
fractures. Several studies have shown no significant
interaction between response to treatment and the presence
or absence of the risk factors used in the present study
including age, height, family history of fracture, low body
weight or BMI, smoking, alcohol intake or prior non-
vertebral fracture [84–88]. In contrast, some risk factors
may be associated with less therapeutic efficacy. For
0
10
20
30
40
50
0123456 0123456
Number of clinical risk factors
10- year hip fracture probability (%)
BMI=20 kg/m2                                            BMD=-2.5 SD
Fig. 6 Ten-year probability of hip fracture (%) in women aged
65 years, according to the number of clinical risk factors. The left-
hand panel shows the probabilities without BMD at a BMI fixed at
20 kg/m
2. The right-hand panel illustrates the effects with BMD fixed
at the threshold for osteoporosis. [05Ca073]
Women
0- 1 - 2 - 3 - 4
Men
0
20
40
60
0- 1- 2- 3- 4
None
Prior fracture
+Glucocorticoids
+Family history
10-year probability (%)
Femoral neck T-score
Fig. 5 10-year probability of a
major osteoporotic fracture in
men and women aged 65 years
according to T-score and clinical
risk factors. Body mass index is
set at 25 kg/m
2. [05Ca136]
Fig. 7 Effect of variations in BMI on 10-year hip fracture probability
(%) in women aged 65 years. Probabilities with BMD are computed at
a T-score of −2.8 SD. [05Ca074]
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falling may respond less completely to agents that preserve
bone mass than patients selected on the basis of low BMD
[89]. This concern is greatest in models that omit BMD,
because pharmacological agents may not be equally
effective across the entire range of BMD [90].
The present model has several unique features. FRAX™
uses Poisson regression to derive hazard functions of death
and fracture. Such hazard functions are continuous as a
function of time, unlike Cox’s regression for which the
corresponding hazard functions are zero except at the time
points of a fracture or death. There are also several
advantages of the Poisson model over logistic regression
analysis. Logistic regression does not take account of when
a fracture occurred, nor whether individuals without a
fracture died or when death occurred. Secondly, for the
assessment of 10-year probabilities by logistic regression,
the observation period should be for 10 years. Moreover,
information longer than the 10-year period cannot be used
for analysis. The cost of ignoring information when
fractures occur and whether and when deaths occur is on
the precision of the estimate. In simulation experiments, the
Poisson model gives the same precision as logistic
regression with fewer numbers of individuals. In our own
simulations in the present context (data on file), the Poisson
model gave the same precision as logistic regression with
half the number of individuals. Finally, the Poisson model
allows adjustments to be made for time trends. The ability
to use several Poisson models permits the use of data from
different sources to integrate fracture and death hazards,
and to calibrate to different countries.
A further feature of the FRAX™ model is that it takes
account of deaths from all causes. In several recent models
of disease probability, this has not been accounted for [23–
25]. For example, the probability of stroke has been
determined as a function of age, race, smoking, body mass
index, atrial fibrillation, HbA1c, systolic blood pressure,
ratio of total to HDL cholesterol and duration of diabetes
[25], but the risk of dying from other reasons was not taken
into account. In the context of osteoporosis, fracture
probabilities are markedly underestimated when no account
is taken of the competing death hazard [27, 35, 36]. For
example, in a study of men followed after orchidectomy,
the cumulative incidence of fractures was 19% after
15 years, but the figure was 40% when deaths were
considered as a competing event [36].
FRAX™ alsotakes account ofthe impactofriskfactors on
the death hazard. For example, smoking and low BMD are
risk factors for fracture but also significant risk factors for
death. Thus, at very low T-scores for BMD, hip fracture
probabilities decreasewithage (seeTable3), in part related to
the higher mortality associated with the lower values for
BMD.
There are several limitations that should be mentioned.
As with nearly all randomly drawn populations, non-
response bias may have occurred. The effect is likely to
exclude sicker members of society, and may underestimate
the absolute fracture risk for example by age. The analyses
also have significant limitations that relate to the outcome
variables and the characterisation of risk factors. The
definition of what was considered to be an osteoporotic
fracture was not the same in all cohorts, but the effect of
this inconsistency is likely to weaken rather than strengthen
the associations that were found. For the hip fracture
outcome, the definition was similar in all cohorts, and may
explain in part the higher risk ratios associated for this
fracture rather than for osteoporotic fracture. Also, the
analyses were confined to clinical fractures, and the results
might differ from vertebral fractures diagnosed by mor-
phometry or as an incidental radiographic finding.
There are also limitations with the risk factors them-
selves. In the case of BMI, this was chosen rather than
weight as the measure for body composition. This has the
advantage that there is less variability across countries and
between sexes. A potential drawback is that BMI can be
influenced by height loss associated with vertebral defor-
mities. Therefore, in individuals with important loss of
height, the risk conferred through BMI could be under-
estimated [91]. The use of maximal attained height, rather
than current height, might be a solution in the future, if it
were shown that fracture risk prediction could be improved.
Further problems relate to the construct of the questions
to elicit the presence or absence of risk factors, which
varied between cohorts. These included questions on family
history, prior fracture, smoking and glucocorticoid use. The
effect of this heterogeneity is likely to weaken rather than
strengthen the associations found. Recall is also subject to
errors and was not validated in any of these cohorts. This is
particularly problematic in the elderly. In addition, the
validity of self-reported alcohol intake is notoriously
unreliable [92]. Indeed, alcohol consumption was signifi-
cantly less in both men and women than that assessed in the
UK[93]. Given that these studies were prospective, however,
much of this error (with the exception of alcohol intake)
should be random, giving rise to non-directional misclassi-
fication. Thus, the associations may actually be stronger than
reported here. Any underestimate may have limited con-
sequences for case-finding, since the populations to be tested
are similar to the populations interrogated. Biases that arise
have more significance where causality is inferred.
A further limitation is that several of the clinical risk
factors identified take no account of dose-response, but give
risk ratios for an average dose or exposure. By contrast,
there is good evidence that the risk associated with excess
alcohol consumption and the use of glucocorticoids is dose-
responsive [14, 94]. In addition, the risk of fracture
Osteoporos Int (2008) 19:385–397 393increases progressively with the number of prior fractures
[95]. These limitations are nearly all conservative.
It should be acknowledged that there are many other risk
factors that might be considered for incorporation into
assessment algorithms. These include BMD at other
skeletal sites, ultrasonography, quantitative computed to-
mography and the biochemical indices of bone turnover.
The available information was too sparse to provide a meta-
analytic framework, but they should be incorporated into
risk assessment algorithms when they are more adequately
characterised. Notwithstanding, the present model provides
a mechanism to enhance patient assessment by the
integration of clinical risk factors alone and/or in combina-
tion with BMD.
The application of this methodology to clinical practice
will demand a consideration of the fracture probability at
which to intervene, both for treatment (an intervention
threshold) and for BMD testing (assessment thresholds).
These are currently being developed for the UK, based on
cost-effectiveness analyses [96]. Intervention thresholds
developed for the United Kingdom may not be applicable
to other countries. The 10-year probability of fracture varies
markedly in different countries [97]. For countries with low
hip fracture rates, as found in developing countries, the
relative risk at which intervention is cost-effective will be
higher, though the absolute risk at which intervention is
cost-effective would not change assuming comparable
costs. Intervention thresholds would, however, change with
differences in costs, particularly fracture costs, which vary
markedly world wide. There is also the issue of affordabil-
ity or willingness to pay for a strategy. The gross domestic
product (GDP) per capita provides an index of affordability.
The GDP varies markedly in different regions of the world.
In the UK, the GDP per capita is estimated at US$ 25,300
in 2002, as compared with US$ 7,000 in Turkey. Thus, for
the same fracture risk and the same costs, treatment will be
less affordable (at least to health services) in Turkey than in
the UK. Nevertheless, individuals in Turkey, rather than
society as a whole, may be willing to pay “United Kingdom
prices” for health care. There is also a marked heterogeneity
in the proportion of GDP devoted to health care, and in the
proportion of the population at risk from osteoporotic
fracture (i.e., elderly people) [98, 99]. For all these reasons,
it is important to define intervention and assessment
thresholds on a country by country basis that takes into
account the setting for service provision and willingness to
pay, as well as considerations of absolute costs.
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Appendix
The estimated hazard functions were of the form
exp β0 þ β1  x1 þ ...þ βk  xk ðÞ ;
where the betas were coefficients and x1, … ,x k were the
values of the variables.
The hazard functions were estimated as continuous
functions by Poisson regression [26, 27].
A separate Poisson regression was performed for each
cohort with men and women included together. Sex was a
variable included in the model. The beta coefficients of the
different variables were merged by the calculation of a
weighted sum. The weights were chosen to give the
smallest variance of the sum. Let vari denote the variance
of βi, and s=Σ (βi/vari), z = Σ (1/vari). Then the merged
beta was β = s/z, and the standard deviation SD of β was
SD=√(1/z). Several variables and their interaction (prod-
ucts) with time, age or sex are included in the model. For
some variables like BMI the change of risk was allowed to
have a different increase or decrease below or above a pre
specified limit.
The hazard functions were estimated by use of many cohorts
from different countries and the data calibrated to the
epidemiology of the UK, assuming that the relative importance
of the variables was approximately the same for different
countries. However, the risk offracture and the risk ofdeath at a
certain age differ from country to country. By considering all
variables except age, a risk score was calculated by
multiplying each variable by the corresponding beta coeffi-
cient and adding the products. The hazard functions are then
calibratedtoaspecifiedcountrysothattherelativeimportance
of the variables except age is preserved, but the mean hazard
function (mean taken over all values of the risk score) equals
the mean risk of the country. The adjusted hazard function is a
product between three factors. The first factor is the natural
number e to the linear combination obtained from the cohorts,
i.e.,etotheriskscore.Thesecondfactoriscalculatedfromthe
general fracture risk among the general population as
described below. The third factor is a normalising factor
making the mean risk equal to the second factor for each age.
Let us denote the third factor z(age). If a random variable Y
has a normal distribution with the mean μ and standard
deviationσthentheexpectedvalueE[exp(Y)]=exp(μ+σ
2/2).
In this application Y is a risk score. By linear regression (in
the simplest case) we determine E[Y∣age] = a + b × age and
the standard deviation σ around the regression line. Then
the third factor z(age), the calibrating one, can be put equal
to 1/exp(a + b × age + σ
2/2).
394 Osteoporos Int (2008) 19:385–397With regard to the relationship between probability and
hazard functions, let h(t) denote the hip fracture hazard
function, d(t) the death hazard function and g(t) the hazard
function of the combined event hip fracture or death.
Though the functions in typical applications contain several
variables, only a time variable is given in order to simplify
the notations. The hazard function g of having the first
event of death or hip fracture is well approximated (see
discussion) by d + h. From the general and well-known
relationship between survival and hazard functions we
know that the probability of being free from any of the
two types of events at the end of the period (0,t) is
exp  
Zt
0
gu ðÞ du
0
@
1
A:
The probability p of a hip fracture event before t is,
therefore, given by
p ¼
Zt
0
h ν ðÞ exp  
Zν
0
gu ðÞ du
0
@
1
Adv
 
Zt
0
h ν ðÞ exp  
Zν
0
hu ðÞ þ du ðÞ ðÞ du
0
@
1
Adv:
The basic relationship between 10-year probability and
the hazard functions of death and of hip fracture includes an
approximation. The hazard function of hip fracture or
death, g(x), is approximately equal to the sum of the hazard
functions of hip fractures and of death, g(x) ≈ h(x) + d(x).
Indeed g(x) is somewhat less than the sum of the two
functions because when a hip fracture causes death, both
will contribute to the right side of the relationship but only
the hip fracture to the left side, so the approximation gives
an underestimation of the probability.
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